Boeringer Ingelheim is a massive diversified company with huge pockets and a major presence worldwide especially in the EU. Do you really think they would just bail on R&D if they thought this was a blockbuster with worldwide potential ANSWER NO. Without a doubt this is GOING to be the most moronic waste of 1B dollars ANY PHARMA COMPANY HAS EVER MADE The FDA first rejected flibanserin in 2010 after a panel of expert advisers unanimously voted against the drug, saying its benefits did not outweigh its risks. The drug's initial developer, Boehringer Ingelheim, abandoned work on the drug in 2011 and sold it to Sprout, a startup headed by a husband-and-wife team from Raleigh, North Carolina. Sprout resubmitted the drug with additional effectiveness and safety data, but the FDA again rejected the drug in October 2013
Why did a big pharma like Merck,Pfizer,Novartis,GSK not jump on this it make no sense. Ready to launch no R&D and they passed that says it all !
Upjohn bailed on pioglitazone and that became a $4 billion product. Viagra was a failed Blood pressure med until Pfizer made it an ED drug.
Lets face it is clear they did not get the job. This is such a unique opportunity with some risk but it a risk worth taking.